DexCom (NASDAQ:DXCM) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research note released on Wednesday morning.

Other equities research analysts have also recently issued reports about the company. Oppenheimer decreased their price objective on DexCom from $150.00 to $115.00 and set an outperform rating for the company in a research note on Friday, July 26th. Barclays reduced their price objective on shares of DexCom from $138.00 to $113.00 and set an equal weight rating for the company in a research note on Monday, July 29th. Royal Bank of Canada lowered their target price on shares of DexCom from $165.00 to $145.00 and set an outperform rating for the company in a research note on Friday, July 26th. Baird R W downgraded DexCom from a strong-buy rating to a hold rating in a research report on Friday, July 26th. Finally, Stifel Nicolaus raised their price objective on DexCom from $90.00 to $100.00 and gave the stock a buy rating in a research report on Friday, August 23rd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $112.25.

DexCom Stock Up 3.7 %

NASDAQ:DXCM opened at $68.11 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a 50-day moving average of $70.19 and a 200 day moving average of $104.95. The firm has a market cap of $27.09 billion, a PE ratio of 43.94, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.34 EPS. As a group, research analysts anticipate that DexCom will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by insiders.

Hedge Funds Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC increased its stake in DexCom by 78.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,218 shares of the medical device company’s stock worth $648,000 after buying an additional 2,299 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of DexCom by 0.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 314,573 shares of the medical device company’s stock worth $39,035,000 after purchasing an additional 1,363 shares in the last quarter. Capital World Investors raised its stake in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in DexCom by 9.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 62,700 shares of the medical device company’s stock valued at $7,780,000 after purchasing an additional 5,256 shares in the last quarter. Finally, Cetera Advisor Networks LLC boosted its stake in DexCom by 24.5% during the 4th quarter. Cetera Advisor Networks LLC now owns 35,920 shares of the medical device company’s stock worth $4,457,000 after purchasing an additional 7,073 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.